TABLE 3

Volume of distribution (V_T) values from multilinear analysis-1

Region	V_T (ml/cm³)
	^aBaseline (%COV)	^{^b}Blocking with LY2456302 (%COV)
		2.5 h Postdose					24 h Postdose
		0.5 mg	2 mg	4 mg	10 mg	25 mg	0.5 mg	2 mg	4 mg	10 mg	25 mg
Amygdala	3.46 (10%)	2.73 (16%)	1.89 (14%)	1.79 (7%)	1.43 (22%)	1.51	3.02 (7%)	2.42 (23%)	2.52 (4%)	1.97 (7%)	1.63
Insula	2.99 (9%)	2.35 (17%)	1.79 (15%)	1.69 (9%)	1.51 (19%)	1.53	2.81 (18%)	2.36 (18%)	2.22 (0%)	1.88 (6%)	1.61
Ant. cingulate cortex	3.00 (8%)	2.37 (14%)	1.73 (17%)	1.72 (10%)	1.51 (18%)	1.56	2.73 (12%)	2.30 (20%)	2.20 (1%)	1.89 (7%)	1.65
Globus pallidus	2.70 (13%)	2.27 (15%)	1.89 (17%)	1.88 (8%)	1.62 (21%)	1.79	2.56 (13%)	2.29 (22%)	2.16 (0%)	1.94 (3%)	1.78
Putamen	2.65 (9%)	2.13 (16%)	1.82 (13%)	1.81 (8%)	1.67 (19%)	1.67	2.47 (16%)	2.21 (15%)	2.10 (1%)	1.91 (3%)	1.73
Temporal cortex	2.42 (7%)	1.98 (15%)	1.64 (13%)	1.65 (10%)	1.53 (18%)	1.52	2.33 (15%)	2.02 (14%)	1.98 (1%)	1.74 (5%)	1.52
Frontal cortex	2.39 (8%)	2.01 (16%)	1.57 (13%)	1.61 (11%)	1.48 (17%)	1.52	2.32 (16%)	1.94 (17%)	1.94 (4%)	1.70 (6%)	1.49
Occipital cortex	2.30 (8%)	1.90 (12%)	1.67 (16%)	1.76 (9%)	1.61 (13%)	1.67	2.18 (9%)	1.99 (13%)	1.99 (3%)	1.80 (4%)	1.67
Hippocampus	2.07 (9%)	1.81 (22%)	1.47 (13%)	1.49 (6%)	1.39 (21%)	1.47	2.05 (30%)	1.63 (18%)	1.69 (0%)	1.61 (7%)	1.50
Caudate	1.90 (11%)	1.43 (9%)	1.33 (12%)	1.39 (11%)	1.29 (28%)	1.36	1.73 (11%)	1.57 (15%)	1.55 (1%)	1.49 (16%)	1.40
Post. cingulate cortex	1.87 (11%)	1.59 (0%)	1.42 (14%)	1.41 (7%)	1.34 (26%)	1.43	1.84 (1%)	1.59 (27%)	1.65 (8%)	1.50 (8%)	1.32
Thalamus	1.88 (7%)	1.75 (12%)	1.68 (9%)	1.70 (8%)	1.60 (22%)	1.75	1.87 (17%)	1.71 (14%)	1.76 (3%)	1.75 (2%)	1.72
Cerebellum	1.86 (18%)	1.53 (18%)	1.44 (15%)	1.57 (14%)	1.43 (14%)	1.52	1.69 (23%)	1.60 (14%)	1.75 (22%)	1.60 (5%)	1.49

↵^a Baseline scans with ¹¹C-LY2795050 (n = 12).
↵^b ¹¹C-LY2795050 PET scans after oral administration of LY2456302 (0.5 mg, n = 2; 2 mg, n = 4; 4 mg, n = 2; 10 mg, n = 3; 25 mg, n = 1).